Update on latent tuberculosis infection

American Family Physician

Volumn 89, Issue 11, 2014, Pages 889-896

  Hartman Adams, Holly ^a   Clark, Karen ^a   Juckett, Gregory ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ALLERGIC REACTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE TRANSMISSION; FEVER; HEALTH CARE CONCEPTS; HEPATITIS; IMMUNITY; INFLUENZA; INTERFERON GAMMA RELEASE ASSAY; LIVER DISEASE; MASS SCREENING; MORBIDITY; NEUTROPENIA; PUBLIC HEALTH; RASH; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; HUMAN; LATENT TUBERCULOSIS; RISK FACTOR;

ANTITUBERCULAR AGENTS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; RISK FACTORS; TUBERCULIN TEST;

EID: 84901773956     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection [published correction appears in MMWR Morb Mortal Wkly Rep. 2012;61(4):80]. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650-1653.
2. National Institute of Allergy and Infectious Diseases. Tuberculosis (TB). http://www.niaid.nih.gov/topics/tuberculosis/Understanding/Pages/overview.aspx. Accessed January 29, 2014.
3. American Thoracic Society; Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4 pt 2):S221-S247.
4. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1995;44(RR-11):19-34.
5. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49(RR-6):1-51.
6. Centers for Disease Control and Prevention. Fact sheet: trends in tuberculosis, 2012. http://www.cdc.gov/tb/publications/factsheets/statistics/TBTrends.htm. Accessed January 29, 2014.
7. Centers for Disease Control and Prevention. Core curriculum on tuberculosis: what the clinician should know. http://www.cdc.gov/tb/education/corecurr/index.htm. Accessed January 29, 2014.
8. Lo Bue P; Centers for Disease Control and Prevention. Travelers' health: chapter 3. Infectious diseases related to travel: tuberculosis. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/tuberculosis.htm. Accessed January 29, 2014.
9. Mazurek GH, Jereb J, Vernon A, Lo Bue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1-25.
10. Tuberculosis. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, Ill.: American Academy of Pediatrics; 2009:680-701.
11. Mancuso JD, Tribble D, Mazurek GH, et al. Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics. Clin Infect Dis. 2011; 53(3):234-244.
12. Hauck FR, Neese BH, Panchal AS, El-Amin W. Identification and management of latent tuberculosis infection. Am Fam Physician. 2009;79(10):879-886.
13. Centers for Disease Control and Prevention. Latent tuberculosis infection: a guide for primary health care providers. http://www.cdc.gov/tb/publications/LTBI/diagnosis. htm#7. Accessed January 29, 2014.
14. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192-1204.
15. Kampmann B, Whittaker E, Williams A, et al. Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J. 2009;33(6):1374-1382.
16. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J. 2011;30(8):694-700.
17. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research [published correction appears in Ann Intern Med. 2007;146(9):688]. Ann Intern Med. 2007;146(5): 340-354.
18. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11-20.
19. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection [published correction appears in MMWR Morb Mortal Wkly Rep. 2012;61(4):80]. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650-1653.
20. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177-184.
21. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011;183(1):88-95.
22. Zhao X, Mazlagic D, Flynn EA, Hernandez H, Abbott CL. Is the QuantiFERON-TB blood assay a good replacement for the tuberculin skin test in tuberculosis screening? A pilot study at Berkshire Medical Center. Am J Clin Pathol. 2009;132(5):678-686.
23. Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011;11:247.
24. Pooran A, Booth H, Miller RF, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med. 2010;10:7.
25. National Institute for Health and Care Excellence. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. http://guidance.nice.org.uk/CG117. Accessed January 30, 2014.
26. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol. 2008;35(7):1271-1276.
27. Centers for Disease Control and Prevention. Tuberculosis (TB) fact sheets. http://www.cdc.gov/tb/publications/ factsheets/testing/IGRA.htm. Accessed January 30, 2014.
28. Mancuso JD, Mazurek GH, Tribble D, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2012; 185(4):427-434.
29. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099-1104.
30. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168(4):443-447.
31. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004; 170(4):445-449.
32. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009;49(12):1883-1889.
33. Hong Kong Chest Service/Tuberculosis Research Centre; Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145(1):36-41.
34. Sterling TR, Villarino ME, Borisov AS, et al.; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155-2166.
35. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173(8):922-926.